Thank you.
Ms. Silverberg, thank you for your testimony. You work for Johnson & Johnson, which is a large pharmaceutical.
You mentioned that in Canada we value health and we want to ensure a healthy population. I think the job of any government is to ensure the success of its people.
Isn't it a bit of a conundrum for Johnson & Johnson that you're developing pharmaceuticals and your number one objective is for shareholder value? That comes in contradiction with developing drugs that would be helping people with rare diseases, because some of those drugs may not be profitable in the market but would do good in terms of the social licence associated with them.
Could you comment on Johnson & Johnson's role as an important stakeholder in developing a solution to this problem?